Examples of using Also section in English and their translations into Danish
{-}
-
Medicine
-
Financial
-
Colloquial
-
Official
-
Ecclesiastic
-
Official/political
-
Computer
See also Section II.
Hypersensitivity see also section 4.4.
See also section B3.
Breast-feeding women see also section 4.6.
See also Section S, point 3 above.
Depression see also section 4.4.
See also Section 6.2,« Data requirements».
Hypersensitivity Reaction see also section 4.8.
See also section 4.8 Undesirable effects.
Hypersensitivity to abacavir see also section 4.4.
See also Section 2.6“Unemployment benefits.”.
SOMAVERT is not recommended during pregnancy see also section 4.6.
See also section"Principal chemical intolerances“.
This forges a strong link with Article 4 see also Section 3.4.
See also section 2 Before you take Norvir.
IALA and IMO, supported by EEC, NA(M) andVTS see also Section 6.2d.
See also Section II, paragraph B, of the preliminary provisions.
Patients at increased risk should be followed closely see also section 4.6.
Gastrointestinal- see also Section G for more general abdominal problems.
The 26 same may be true for ketamine anddextromethorphan see also section 4.4.
See also Section II.C of this report.(2)Agreement between the European Communities and the Government.
Confusion, Anxiety, Emotional lability,Suicide attempt see also section 4.4.
Source: ECB. Notes: See also Section 3.1 in the“Euro area statistics” section of the ECB's Monthly Bulletin.
After reconstitution, an immediate use is recommended see also section 6.4.
Only the highest frequency observed in the trials is reported 1 see also section infection below 2 see also section haematologic adverse reactions below 3 see also section infusion-related reactions below.
The same may be true for ketamine anddextromethorphan see also section 4.4.
In study AI455-094(see also section 4.6), the safety follow-up period was restricted to only six months, which may be insufficient to capture long-term data on neurological adverse events and mitochondrial toxicity.
Losartan is also not recommended in children with hepatic impairment see also section 4.4.
Preliminary safety data from this study(see also section 4.8), showed an increased infant mortality in the stavudine+ didanosine(10%) treatment group compared to the stavudine(2%), didanosine(3%) or zidovudine(6%) groups, with a higher incidence of stillbirths in the stavudine+ didanosine group.
This is a prerequisite for ensuring equivalence among the product systems see also section 3.3.